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Pityriasis rubra pilaris (PRP) is a rare papulosquamous skin disorder, which is pheno­
typically related to psoriasis. Some familial PRP cases show autosomal dominant 
inheritance due to CARD14 mutations leading to increased nuclear factor κB (NFκB) 
activation. Moreover, CARD14 polymorphisms have also been implicated in sporadic 
PRP. A Hungarian PRP patient with childhood onset disease showing worsening of the 
symptoms in adulthood with poor therapeutic response underwent genetic screen­
ing for the CARD14 gene, revealing four genetic variants (rs117918077, rs2066964, 
rs28674001, and rs11652075). To confirm that the identified genetic variants would 
result in altered NFκB activity in the patient, functional studies were carried out. 
Immunofluorescent staining of the NFκB p65 subunit and NFκB­luciferase reporter 
assay demonstrated significantly increased NFκB activity in skin samples and kera­
tinocytes from the PRP patient compared to healthy samples. Characterization of the 
cytokine profile of the keratinocytes and peripheral blood mononuclear cells demon­
strated that the higher NFκB activation in PRP cells induces enhanced responses to 
inflammatory stimuli. These higher inflammatory reactions could not be explained solely 
by the observed CARD14 or other inflammation­related gene variants (determined by 
whole exome sequencing). Thus our study indicates the importance of investigations 
on other genetic factors related to PRP and their further functional characterization to 
bring us closer to the understanding of cellular and molecular background of disease 
pathogenesis.
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INtRoDUCtIoN
Pityriasis rubra pilaris (PRP; OMIM 173200) is a rare papulosquamous skin disorder, which is 
characterized by keratotic follicular papules, orange-red colored exfoliative dermatitis embrac-
ing "sparing islands" of normal skin and palmoplantar hyperkeratosis (1–4). PRP is usually 
self-limiting and the symptoms resolve within a few years after the onset of the disease (5). 
Histologically, PRP is characterized by alternating ortho- and parakeratosis oriented in vertical 
and horizontal directions ("checkerboard pattern"), irregular acanthosis, follicular plugging, 
perivascular lymphocytic infiltration of the dermis, and absence of neutrophils in the epidermis 
(1, 4, 6). Most cases of PRP are sporadic with multifactorial etiology; however, familiar forms 
FIgURe 1 | Clinical and histological image of the type V Pityriasis rubra pilaris 
(PRP) patient. (a) Erythematosus, hyperkeratotic confluent thin plaques with 
fine scales on the trunk of the patient. (B) There is follicular plugging with 
alternating hyper­ and parakeratosis in the epidermis accompanied by 
granulosis, acanthosis, and mild spongiosis. A moderate lymphocytic infiltrate 
can be seen in the papillary dermis. The diagnosis of PRP has been 
confirmed by the histology (HE, digitally scanned slide).
2
Danis et al. CARD14 Variants in PRP
Frontiers in Immunology | www.frontiersin.org July 2018 | Volume 9 | Article 1564
were also described. Type V atypical juvenile variant accounts 
for approximately 5% of PRP cases with an early onset and 
prolonged course, with usually familial origin due to gain- 
of-function mutations in the caspase recruitment domain family 
member 14 (CARD14) gene (3, 4, 6, 7). CARD14 protein is pre-
dominantly expressed in the skin, and plays an important role 
in regulation of skin inflammation by activating nuclear factor 
κB (NFκB) signaling. Certain CARD14 mutations are thought 
to cause abnormal inflammatory response and thus, contribute 
to the development of PRP (3, 8–10).
Pityriasis rubra pilaris is often misdiagnosed as psoriasis (11), 
a more common papulosquamous inflammatory disorder affects 
approximately 2% of the European populations (12). The acute 
form of psoriasis includes guttate, pustular, and erythrodermic 
variants, while the chronic form includes plaque-type and flexural 
variants (13). Histologically, psoriasis is featured by parakeratosis, 
thickened projections of the prickle cell layer of keratinocytes, 
absence of the granular layer and polymorphonuclear leukocytic 
and lymphocytic infiltrates in the dermis and epidermis (14, 15). 
Psoriasis also exhibits multifactorial etiology (16–19). Variants 
identified to date that confer susceptibility explain less than 
20% of psoriasis cases (20, 21). The remaining 80% of cases is 
presumed to be the consequence of yet unidentified susceptibility 
loci and environmental factors (8).
Recent studies demonstrated that CARD14 variants and 
NFκB activation mediated by mutant CARD14 is implicated in 
the development of both PRP and psoriasis and its rare variants 
have also been implicated in the development of generalized 
pustular psoriasis (8, 22–24). Similarly to its homologous protein 
CARD11, activated CARD14 interacts with the CBM-complex, 
namely the B-cell chronic lymphocytic leukemia/lymphoma 
10 protein, which activates the mucosa-associated lymphoid 
tissue lymphoma translocation protein 1 a key member in the 
downstream activation of the NFκB pathway (6, 8, 25, 26). 
Germline mutations in the members of this signaling cascade are 
implicated in a broad spectrum of immune disorders, including 
severe immune deficiencies, lymphoproliferative disorders, and 
immune-mediated skin diseases (3, 22, 25–29).
Here, we report the detailed investigation of a Hungarian 
patient who was diagnosed with familial PRP based on clinical 
and histological findings and had family members suffering from 
psoriasis. Besides the analysis of the patient’s genetic background, 
we examined the NFκB activity of the patient’s samples by 
multiple methods.
Case RepoRt
pRp patient
The 61-year-old Hungarian woman was referred to the out-
patient clinic of the Department of Dermatology and Allergology 
(Szeged; Hungary). Generalized erythroderma with mild 
infiltration and whitish fine scales were observed on her body 
(Figure 1A). The first onset of her skin symptoms occurred in 
childhood and she was under regular dermatological care for 
28 years. Previous phototherapy and oral acitretin (25 mg/day) 
therapy were not effective, while methotrexate therapy was 
aborted due to serious side effects. Based on clinical and his-
tological findings (Figure 1B) atypical PRP phenotype was diag-
nosed. Since the patient developed symptoms in early childhood 
turning into a chronic course with no sustained clearance, our 
patient was classified as a PRP type V patient. The patient was 
not aware of any family members affected by PRP; however, both 
her daughter and a grandchild had psoriasis and were also under 
regular dermatological care.
genetic screening Identified CARD14 
Variants in the pRp patient
The association between CARD14 gene variants and PRP has 
recently been reported (3, 7). Direct sequencing of the CARD14 
coding regions of the PRP patient revealed three heterozygous 
missense variants: c.1641G/C p.Arg547Ser (rs2066964) in exon 
14, c.2044C/T and p.Arg682Trp (rs117918077) in exon 17, and 
c.2458C/T p.Arg820Trp (rs11652075) in exon 20. The patient 
carried a splice site variant in homozygous form c.676-6G/A 
(rs28674001), located six nucleotides away from the 5′ end of 
exon 7. According to the results of analysis with pathogenicity 
prediction tools, the p.Arg682Trp missense variant is expected 
to be pathogenic, whereas the other three variants are expected 
to be benign.
Increased NFκB activity in the pRp 
patient’s skin samples and Keratinocytes
Previous studies suggested that CARD14 variants contribute to 
the development of PRP by increasing the activity of the NFκB 
FIgURe 2 | Lesional Pityriasis rubra pilaris (PRP) skin samples and keratinocytes exhibit higher nuclear factor κB (NFκB) activation compared to healthy samples. 
Skin­biopsy sections obtained from the PRP patient [lesional area: (a,D) non­lesional area (B,e)] and from a healthy individual (C,F) were stained with antibodies 
against the p65 subunit of NFκB. Nucleic staining of p65 comprises of active NFκB. Arrows indicate the p65­positive nuclei in the lesional PRP samples (a–D), while 
no nuclear p65 staining was observed in the healthy and non­lesional PRP skin (Bar = 100 μm, healthy samples are representative for two individuals). Higher basal 
NFκB activity was observed in the cultured PRP keratinocytes compared to healthy keratinocytes by NFκB­luciferase reporter assay (g). Cells were co­transfected 
with the pNFκB­luc Cis­Reporter Plasmid and the pGL4.75 control plasmid [hRluc/CMV]. The luciferase activity derived from the NFκB­luc plasmid was normalized 
to the activity of Renilla luciferase activity from the pGL4.75 [hRluc/CMV] plasmid, and compared to the luciferase activity of the healthy samples. Data are 
represented as mean ± SE, significance was determined by Student’s t­test; ***p < 0.001.
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signaling pathway (3, 6). To investigate whether the detected 
CARD14 variants in the investigated PRP patient increase NFκB 
activity, immunofluorescent (IF) staining was performed on 
paraffin-embedded samples of lesional and non-involved skin 
from the PRP patient and from healthy individuals (Figure 2). IF 
staining of the NFκB p65 subunit demonstrated that p65-positive 
nuclei (in 31.68% of epidermal cells) were present in the supra-
basal epidermis of the lesional PRP skin, but were not present in 
the non-involved skin of the PRP patient or in the healthy skin 
samples. Moreover, analysis of fluorescence intensity revealed a 
stronger staining in PRP samples compared to healthy samples 
(Figure S2A in Supplementary Material). As an additional con-
trol group, patients with moderate-to-severe psoriasis vulgaris 
(PASI 22.4 and PASI 4.1) were also enrolled into the study, but 
p65-positive nuclei were not found either in lesional or non-
lesional samples from psoriatic patients (Figures S4 and S5 in 
Supplementary Material). Among all examined sections, p65 
appeared in the nuclei in the epidermis exclusively of the lesional 
skin from the PRP patient.
To further confirm increased NFκB activity in keratinocytes 
from the PRP patient, an NFκB-luciferase reporter assay was 
performed. The NFκB activity was significantly higher in the 
cultured keratinocytes of the PRP patient compared to healthy 
keratinocytes (Figure 2G).
In parallel, IF staining of the NFκB p65 subunit was also 
performed on peripheral blood mononuclear cells (PBMCs) 
derived from the PRP patient and healthy individuals (Figure 
S3 in Supplementary Material). Staining was more intense in the 
PBMCs of the PRP patient compared to cells of healthy individuals 
(Figure S2B in Supplementary Material). These results demon-
strated increased NFκB activity in various cell types derived from 
the PRP patient.
Both pRp pBMCs and Keratinocytes 
express and secrete elevated Levels  
of Inflammatory Cytokines
To determine whether the increased NFκB activation had any 
functional consequence in the PRP patient, expression and secre-
tion of NFκB-induced cytokines were determined.
Keratinocytes of the PRP patient showed a tendency for 
higher basal mRNA expression and significantly higher secre-
tion of interleukin (IL)-1α and IL-1β compared to healthy 
NHEKs (Figure 3). Upon LPS treatment in healthy keratino-
cytes mRNA expression induction was only detected for IL-1α 
(Figure 3A).
We found a significantly higher basal mRNA expression of 
IL-1α, IL-1β, IL-6, IL-8, and tumor necrosis factor (TNF)-α in 
PBMCs of the PRP patient compared to healthy control (Figure 4). 
In healthy PBMCs, LPS treatment significantly induced the 
mRNA expression of IL-1β and IL-8 compared to the untreated 
control samples, while in the PRP PBMCs significant induction 
(p < 0.001) was observed upon LPS treatment for all examined 
cytokines. The induction of IL-1α, IL-6, IL-8, and TNF-α was 
significantly (p < 0.05) higher in PRP cells compared to healthy 
control. The unstimulated PRP PBMCs secreted IL-8, while the 
secretion of the other cytokines was detected only after LPS 
treatment. IL-1α, IL-1β, and TNF-α were secreted at significantly 
FIgURe 4 | mRNA expression and secretion of inflammatory cytokines in peripheral blood mononuclear cells (PBMCs). IL­1α (a), IL­1β (B), IL­6 (C), IL­8 (D), and 
tumor necrosis factor (TNF)­α (e) mRNAs were detected in PBMCs derived from healthy (white) or Pityriasis rubra pilaris (PRP) (gray) cells 6 h after treatment with 
100 ng/ml LPS. Secretion of IL­1α (F), IL­1β (g), IL­6 (H), IL­8 (I), and TNF­α (J) was detected for PBMCs derived from a healthy individuals (white, n = 3) or the 
PRP patient (gray, n = 1) 6 h after treatment with 100 ng/ml LPS. Data are represented as mean ± SE; statistical significance was determined by ANOVA *p < 0.05; 
**p < 0.01; and ***p < 0.001.
FIgURe 3 | mRNA expression and secretion of inflammatory cytokines in keratinocytes. The mRNA expression of IL­1α (a) and IL­1β (B) and CARD14  
(C) measured by RT­PCR and secretion of IL­1α (D) IL­1β (e) measured by ELISA were detected in keratinocytes derived from a healthy individual (white bars)  
and the Pityriasis rubra pilaris (gray bars) patient 6 h after treatment with 500 ng/ml LPS, time matched, and untreated samples served as controls. mRNA 
expression was normalized to the 18S rRNA expression and compared to the expression level of the untreated healthy control samples. Data are represented  
as mean ± SE of three experiments; *p < 0.05.
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higher levels in PRP cells compared to the PBMCs of healthy 
controls (Figure 4).
No significant difference was found between the basal 
CARD14 mRNA expression of healthy and PRP keratinocytes, 
but in healthy keratinocytes LPS treatment decreased CARD14 
expression significantly, while CARD14 levels in PRP keratino-
cytes were not affected (Figure 3E).
MateRIaLs aND MetHoDs
genetic Investigation
Blood samples were taken from investigated individuals (one PRP 
patient, psoriatic patients n = 2, and healthy individuals n = 5). 
Written informed consent was obtained from all investigated 
individuals to participate in the study and for the publication 
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of this case report. The study was approved by the Human 
Investigation Review Board of the University of Szeged and 
complied with the ethical standards of research and in accordance 
with the Helsinki Declaration. Genomic DNA was isolated with 
QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, Germany). 
After amplifying the coding regions and flanking introns of the 
CARD14 gene using primer sequences displayed on the UCSC 
Genome Browser (30) and DNA sequencing was performed on 
amplification products.
The identified variants were analyzed with SIFT (31–36), 
PROVEAN (37–39), and PolyPhen-2 (40, 41) using online 
prediction tools for in silico analysis of their putative pathogenic 
role. Results of the genetic screening of all investigated indivi-
duals are described in Table S1 in Supplementary Material.
Cell Culture and sample preparation
Peripheral blood mononuclear cells were isolated from whole 
blood of the PRP patient and three healthy individuals with a 
density-gradient centrifugation method using Ficoll-Paque. 
PBMCs were washed twice with phosphate-buffered saline (PBS) 
and seeded into 24-well plate at a density of 106 cells/ml in RPMI 
1650 media supplemented with 10% fetal bovine serum, 1% anti-
biotic/antimycotic solution (PAA Laboratories GmBH, Pasching, 
Austria), and 1% l-glutamine (PAA Laboratories). PBMCs were 
treated with 100  ng/ml LPS (Sigma Aldrich, St. Louis, MO, 
USA) for 6 and 24 h immediately after isolation. Time matched, 
untreated samples were used as controls, samples were harvested 
for RNA isolation and IF staining.
Human epidermal keratinocytes were isolated from two 
6  mm punch biopsies derived from lesional skin of the 
lumbosacral region of the PRP patient and from a healthy 
skin specimen obtained from the Plastic Surgery Unit of our 
Department. The epidermis and the dermis were separated by 
overnight incubation in Dispase (Roche Diagnostics, Manheim, 
Germany), and keratinocytes were obtained after maceration in 
0.25% trypsin. Cells were grown in 75 cm2 cell culture flasks 
for three passages in keratinocyte serum-free medium which 
contained epidermal growth factor and bovine pituitary extract 
(Gibco Keratinocyte SFM Kit; Life Technologies, Copenhagen, 
Denmark), supplemented with 1% antibiotic/antimycotic solu-
tion and 1% l-glutamine at 37°C in a humidified atmosphere 
with 5% CO2. Third passage keratinocytes were seeded into 
12-well plate at a density of 150,000 cells/ml and 24 h later were 
treated with 500 ng/ml LPS for 6 h. Time matched, untreated 
samples were used as controls, samples were harvested for RNA 
isolation.
NFκB-Luciferase Reporter assay
Keratinocytes were seeded into 12-well plate at a density of 
150,000 cells/ml in keratinocyte serum-free medium. 24  h 
later cells were transfected with the pNFκB-luc Cis-Reporter 
Plasmid (Stratagene) reporter construct vector and the pGL4.75 
[hRluc/CMV] plasmid (Promega) internal control using the 
X-tremeGeneHP transfection reagent (Roche Diagnostics). 24 h 
after transfection, cells were washed in PBS and lysed in passive 
lysis buffer (Biotium, Hayward, CA, USA). Luciferase activity 
of the lysates was measured using the Firefly & Renilla Dual 
Luciferase Assay Kit (Biotium) and Thermo Luminoskan Ascent 
software (Thermo Scientific, Rockford, IL, USA), according to 
the manufacturer’s instructions. Luciferase activity derived from 
NFκB-luc plasmid was normalized to the activity of Renilla 
luciferase activity from the pGL4.75 [hRluc/CMV] plasmid. 
The transfection efficiency was similar in the PRP patient 
and healthy-control-derived keratinocytes, as determined by 
the transfection of a GFP reporter construct (Lonza, Basel, 
Switzerland) and flow cytometry.
Immunofluorescent staining
Peripheral blood mononuclear cells were harvested and 105 cells 
were centrifuged onto a slide by a cytocentrifuge (Cytopro™, 
Wescor, Logan, UT, USA) and dried overnight at room tempera-
ture. The slides were fixed in 2% paraformaldehyde for 20 min. 
Skin specimens from healthy (n = 2), PRP (n = 1), and psoriatic 
patients (n = 2) were fixed in 4% buffered formaldehyde for 24 h. 
The tissue sample was subjected to paraffin embedding, and 
4-μm-thick sections were placed on silanized slides, dewaxed in 
xylene for 3-times 5 min and rehydrated in decreasing concentra-
tions of ethanol. Tissue retrieval was performed in citrate buffer 
(10 mM, pH 6.0).
Slides were exposed to 1% goat serum containing 1% bovine 
serum albumen (BSA) in PBS for 30 min. Slides were incubated 
overnight at 4°C with NFκB-p65 polyclonal antibody (rabbit 
IgG, 1:500; Santa Cruz Biotechnology, Dallas, TX, USA) in 1% 
BSA-PBS. Normal rabbit IgG antibody (Santa Cruz) was used 
as isotype control. Anti-rabbit Alexa Fluor 546 goat secondary 
antibody (Sigma Aldrich; 1:500) was applied for 2 h at room tem-
perature. Cell nuclei were counterstained with 4,6-diamidino-
2-phenylindole (DAPI, Sigma Aldrich, 1:500) and moun ted 
with Fluoromount-G (Southern Biotech, Birmingham, 
AL, USA).
IF pictures were taken with the aid of a Zeiss Axio Imager 
fluorescent light microscope (Carl Zeiss MicroImaging) fitted 
with a Carl Zeiss AxioCam MRc5 camera. Fluorescence intensity 
of staining was quantified by the ImageJ software (developed by 
NIH).
Real-time Rt-pCR
Peripheral blood mononuclear cells and keratinocytes were 
harvested using TRIzol® Reagent (Invitrogen Corp., Carlsbad, 
CA, USA), following the manufacturer’s instructions. cDNA 
was synthesized from 1  µg total RNA using the iScript cDNA 
Synthesis Kit (Bio-Rad Laboratories, Hercules, CA, USA). Real-
time RT-PCR experiments were carried out with the Universal 
Probe Library system (Roche Diagnostics) using a C1000 Touch 
Thermal Cycler (Bio-Rad Laboratories). Primers are listed as 
Table S2 in Supplementary Material.
eLIsa
Cell supernatants were centrifuged (8,000  rpm, 5 min, 4°C) to 
pellet cell debris and the amount of IL-1α, IL-1β, IL-6, IL-8, and 
TNF-α was determined by ELISA (R&D Systems, Minneapolis, 
MN, USA), according to the manufacturer’s instructions.
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statistical analysis
Experiments were carried out in triplicates; results are represented 
as mean ± SE. For statistical analysis, one-way ANOVA was used 
to compare more than two groups, and one-tailed, T-test was 
used to compare two groups. Statistical analysis was carried out 
with R software (Ver. 3.2.2.) with a significance level of p < 0.05.
DIsCUssIoN
CARD14 has a well-established immunomodulatory function: 
it plays an important role in the regulation of inflammation by 
activating the NFκB signaling pathway (3, 10) through its coiled-
coil domain (42), and missense variants of this domain were 
shown to alter NFκB activation (8).
The CARD14 variants identified in this study are located 
within different domains of the protein. The c.676-6 G/A splice 
variant is a frequent variant in the population (MAF =  0.34) 
located in the intronic region between the two exons encoding 
the NFκB activating coiled-coil domain. The p.Arg682Trp mis-
sense variant with a low minor allele frequency (MAF~0.01) is 
located on the SH3 domain. The more common p.Arg547Ser 
missense variant (MAF = 0.37) is located in the looping region 
between the coiled-coil domain and the PDZ domain, and the 
p.Arg820Trp (MAF =  0.35) missense variant is located on the 
catalytically inactive guanylate kinase domain.
Genetic variants of CARD14 were described to affect NFκB 
activation in both psoriasis and PRP; however, the level of NFκB 
activation does not correlate with the severity of the disease 
or with the disease phenotype (8). CARD14 mutations have 
been previously linked to type V PRP (7), which, due to the 
autoinflammatory pathogenic mechanism caused by mutation 
to CARD14, was recently characterized by Akiyama and col-
leagues as "autoinflammatory keratinization diseases" (43, 44). 
Association of the rs2066964 (encoding for p.Arg547Ser) muta-
tion with psoriasis was found in some cohorts (8) and in patients 
with severe pustular psoriasis (45), and it was also detected 
with high frequency among sporadic PRP patients (6, 9). The 
rs117918077 (encoding for p.Arg682Trp) polymorphism of the 
CARD14 gene has been associated with the development of pso-
riasis and it has also been previously identified in sporadic PRP 
patient (6, 8). The rs28674001 intron variant was described in PRP 
patients as neutral (6). The common missense variant rs11652075 
polymorphism (encoding for p.Arg820Trp) showed association 
with psoriasis in several cohorts (8, 29), moreover, it was found 
in sporadic PRP patients (6, 9).
CARD14 is expressed predominantly in the skin (3). CARD14 
expression was similar in both healthy and PRP keratino-
cytes, however, in contrast to healthy cells PRP keratinocytes 
showed no response to LPS, suggesting an aberrant regulation 
of CARD14 and subsequent processes in PRP. IF staining and 
NFκB-luciferase reporter assay demonstrated that NFκB acti-
vity was 2.5-fold higher in the PRP patient harboring all four 
CARD14 variants than in healthy controls. Moreover, the higher 
NFκB activation in PRP cells was associated with higher cytokine 
responses both in PBMCs and cultured keratinocytes.
In previous studies the functional effects of the p.Arg682Trp 
and p.Arg547Ser variants have been investigated separately, 
using site-directed mutagenesis and a NFκB-luciferase reporter 
assay, which revealed no exerted effect of these variants on NFκB 
activation (6, 8). No previous functional data are available about 
the ability of the c.676-6G/A and p.Arg820Trp polymorphisms to 
influence NFκB activation.
Skin samples of PRP patients, not carrying any rare CARD14 
variants, also showed higher NFκB activation (46), which might 
be caused by the prolonged inflammatory milieu in the PRP 
patients body. The high population frequency of our observed 
polymorphisms and the previous finding on their inability to 
affect NFκB activation on their own (6, 8) suggest that their 
collective presence in the patient might not be the solely cause 
of the increased NFκB activation observed in patient samples. 
In line with these findings, our results showed increased NFκB 
positivity in skin samples and PMBCs of the PRP patient, which 
might be caused by the inflammatory phenotype of the patient. 
However, the patient’s keratinocytes, which were cultured for 
three passages in a non-inflamed environment, still maintained 
their higher NFκB activity. These results still suggest an inherited 
nature of the more intense NFκB responsiveness of our PRP 
patient.
Screening of the genes encoding members of the CBM signa-
losome complex and up- and downstream signaling by whole 
exome sequencing revealed no putative pathogenic sequences 
(Table S3 in Supplementary Material.), therefore, we exclude 
their involvement in the enhanced NFκB activity of this PRP 
patient. We assume that the cumulative effect of the CARD14 
genetic variants is one of the factors contributing to the increased 
NFκB activity of keratinocytes and PBMCs, which might lead to 
the development of PRP in the patient; however, the presence 
of yet unidentified variants in other genes cannot be excluded. 
Such variants could explain why only the investigated patient is 
affected by PRP while other family members are suffering from 
psoriasis. Unfortunately, family members of the patient have not 
agreed to undergo genetic screening, thus we were not able to 
identify these differentiating factors.
Pityriasis rubra pilaris is a complex inflammatory dermatosis 
with multifactorial etiology. Although CARD14 mutations iden-
tified in familial cases may provide an insight into the deregulated 
inflammatory processes in the disease, its exact pathogenesis 
remains to be elucidated. Our results highlight the possibility of 
other yet not identified inherited factors in the development of 
both PRP and psoriasis. High-throughput genetic analyses could 
shed light on other genes related to the disease.
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